FDA approves Bavarian's Jynneos vaccine to be marketed to prevent smallpox and monkeypox infections
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
today (September 25),'sFDA(http://)approved the company's Jynneos vaccine to prevent smallpox and monkeypox infections among high-risk adults over the age of 18,
the'sand the fda'sannounced today http:// (September 25)About Jynneos
The Development of The Tinneos by Bavarian Nordic is a weakened bovine pox virus that does not replicate proliferationIt cannot be replicated in the human body, but it still stimulates a powerful immune responseJynneos was developed in collaboration with the U.Sgovernment to make smallpox protectable for all populationsJynneos' approval is based on the results of 22 clinical trials (http:// , including two Phase 3 clinical trials In the trial, Jynneos met the non-performance standard in terms of immunogenicity compared to the replica smallpox vaccine ACAM2000 In terms of safety
the safety of Jynneos was tested in the of people who had not received the smallpox vaccine health (http:// healthy people who had received the smallpox vaccine, HIV-infected patients and patients with atopic dermatitis
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
